韩国累计7,567人接种阿斯利康疫苗後出现疑似异常反应
《韩联社》报道,根据韩国新冠疫苗预防接种推进团数据,当地接种新冠疫苗後疑似异常反应个案累计增加7,648宗,当中61宗为疑似过敏反应病例,疑似重症5宗,死亡15宗,其余为轻微症状。
其中有7,567宗涉及阿斯利康(AZN.US)疫苗,占比达98.9%,其余81人接种的为辉瑞(PFE.US)疫苗。当局指,可能是由於阿斯利康疫苗接种人数超过52.6万人,远多於辉瑞疫苗接种人数1.98万人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.